WX-UK1
DCTPepD ID DCTPepD0085
Active Ingredients WX-UK1
Description A 3-amidinophenylalanine-based non-cytotoxic small molecule that belongs to a new class of drugs. In animal models, WX-UK1 blocks tumor cell invasion, metastasis and primary tumor growth by inhibiting serine proteases and the urokinase Plasminogen Activator (uPA) system, which have been shown to play a key role in metastasis and primary tumor growth of breast, gastric, colon cancer, and various other solid tumors.
Synonyms WX UK1; WX-UK1
Disease Solid tumors
Classification
Amino acid and derivative
Structure Information
Molecular Formula C32H48ClN5O5S
Molecular Weight 649.3
Active Sequence Not available
Sequence Length Not available
Modification Not available
IUPAC Name ethyl 4-[(2S)-3-(3-carbamimidoylphenyl)-2-[2,4,6-tris(propan-2-yl)benzenesulfonamido]propanoyl]piperazine-1-carboxylate hydrochloride
InChI InChI=1S/C32H47N5O5S.ClH/c1-8-42-32(39)37-14-12-36(13-15-37)31(38)28(17-23-10-9-11-24(16-23)30(33)34)35-43(40,41)29-26(21(4)5)18-25(20(2)3)19-27(29)22(6)7;/h9-11,16,18-22,28,35H,8,12-15,17H2,1-7H3,(H3,33,34);1H/t28-;/m0./s1
InChI_Key FMHIVIJVVYYSRN-JCOPYZAKSA-N
SMILES O=C(N1CCN(C([C@@H](NS(=O)(C2=C(C(C)C)C=C(C(C)C)C=C2C(C)C)=O)CC3=CC=CC(C(N)=N)=C3)=O)CC1)OCC.[H]Cl
External Codes
PubChem CID 9939426
DrugBank Accession Number DB05476
NCI Thesaurus Code Not available
UNII UJ925Q0P3B GSRS
CAS 255374-84-6
Drug approval
Drug indication
Investigated for use/treatment in solid tumors.
The drug is not approved.
| ClinicalTrials.gov Identifier | Title | Condition or disease | Phase | Purpose |
|---|---|---|---|---|
| NCT00083525 | Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignancies | Advanced Malignancies | Phase 1 | Treatment |
More clinical information is obtained from ClinicalTrials.gov.
